Alzheimer’s disease is the sixth leading cause of death in the U.S. Despite decades of research, there’s still no cure, and few options to slow or minimize symptoms. The last Alzheimer’s drug was approved more than 15 years ago, but a new campaign, called Disrupting Dementia, hopes to drive new diagnostics and treatments while also supporting patients and families affected by this devastating condition.
Health and Human Services Secretary Alex Azar and Centers for Medicare & Medicaid Services Director Seems Verma are crisscrossing the country to tout the Trump administration’s plan to combat prescription drug prices. They promise that America’s Patients First, released by the president and HHS on May 11, will address significant roadblocks to lowering drug costs.
People age 65 and older account for 34 percent of all prescription medication use and 30 percent of all over-the-counter drugs purchased, according to this Medscape article. Azar, a former drug company executive, recently spoke with reporters and other stakeholders to promote the plan, saying that high prescription costs seriously threaten too many Americans’ health and wellbeing. Continue reading
If you are familiar with Drugs@FDA, you know that the website allows you to quickly look up a drug by its name (brand), the active ingredient (generic), or application number. But if you frequently work on the go or need to look up something quickly while away from your computer, you now can download the FDA’s new app, Drugs@FDA Express (iOS/Apple and Android/Google), to see much of the same information.
Released in late March, the app is pretty basic, but often that’s the best kind of app. It loads quickly, isn’t overly cluttered and has simpler user-friendly interface. The opening page is straightforward. Continue reading
Last week, President Trump spoke about his plans to lower prescription drug prices by increasing competition and creating incentives for them to lower prices.
His plan includes budget proposals to reform the Medicare Part D program, curbing abuse of FDA safety rules and continuing generic drug approvals,
Public Citizen’s Health Research Group today released an updated report cataloging all major financial settlements that the pharmaceutical industry has been forced to sign with federal and state governments from 1991 through 2017 for illegal activities.
The report shows a dramatic decrease since 2013 in both the total amount paid and the average penalty. Additionally, it found that state governments have virtually stopped prosecuting pharmaceutical manufacturers on their own initiative and with their own resources. Continue reading
Taken at face value, Right-to-Try (RTT) legislation sounds like a no-brainer, promising to improve access to treatments yet unapproved for marketing by the FDA for people with terminal illnesses. But it’s not that simple, according to Alison Bateman-House, Ph.D., M.P.H., M.A., an ethicist and assistant professor at the New York University School of Medicine.
In fact, many of its basic provisions make it unlikely to deliver on its promise. At a New York City Metro AHCJ Chapter meeting in November, she discussed reasons for her argument that RTT will only serve to limit, rather than expand, access to potentially life-saving treatments. Continue reading